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ABSTRACT 
Image analysis is a cost-effective tool to associate complex features of tissue organisation with 
molecular and outcome data. Here we predict consensus molecular subtypes (CMS) of colorectal 
cancer (CRC) from standard H&E sections using deep learning. Domain adversarial training of a 
neural classification network was performed using 1,553 tissue sections with comprehensive multi-
omic data from three independent datasets. Image-based consensus molecular subtyping (imCMS) 
accurately classified CRC whole-slide images and preoperative biopsies, spatially resolved 
intratumoural heterogeneity and provided accurate secondary calls with higher discriminatory power 
than bioinformatic prediction. In all three cohorts imCMS established sensible classification in CMS 
unclassified samples, reproduced expected correlations with (epi)genomic alterations and effectively 
stratified patients into prognostic subgroups. Leveraging artificial intelligence for the development of 
novel biomarkers extracted from histological slides with molecular and biological interpretability has 
remarkable potential for clinical translation.  
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INTRODUCTION 
Colorectal cancer (CRC) is a disease with heterogeneous molecular subtypes, variable clinical course 
and prognosis (1). An increasing understanding of CRC biology has led to the development of 
targeted treatments directed against key pro-oncogenic signalling pathways, but these treatments are 
only effective in a small proportion of patients (2, 3). Molecular stratification of CRC patients is 
essential to form homogenised subgroups for personalised treatment and prognosis (4). Next 
generation sequencing (NGS) technologies enable the multi-omic profiling of malignant tumours but 
impact on clinical practice has been limited. This is due to high costs, difficulty in the standardisation 
of pre-analytical procedures, requirements for data storage and bioinformatics expertise (5, 6). In 
contrast, histopathology slides are inexpensive to produce and principal stains such as haematoxylin 
and eosin (H&E) are firmly established in the pathology lab.  
The application of traditional image analysis to histopathology facilitates the quantitative assessment 
of tissue architecture, cell distribution, and cellular morphology by light microscopy to generate feature 
libraries of unprecedented resolution and detail (7). More recently, deep learning is used to capture 
morphological differences with a precision that exceeds human performance. Coudray et al utilise this 
approach to detect targetable oncogenic driver mutations in lung cancer using deep neural 
classification networks (8). By combining an image-based analysis with molecular characterisation, it 
becomes feasible to identify novel genotype-phenotype correlations. For the first time it is now 
possible to characterise complex multi-scale morphological traits as well as genomic alterations at 
scale. Given that H&E processing allows analysis of large tissue sections at low cost and with short 
turn around without the need to modify existing clinical workflows, the discovery of morpho-molecular 
correlations holds the promise of revolutionising patient stratification in clinical practice (9). Image-
based methods are suitable for prioritisation of certain patient samples for additional molecular testing 
and for provision of additional guidance for the selection of tissue blocks. Ultimately, the biological 
interpretability of genomic alterations could revolutionise the development of new biomarkers.  
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In CRC, it is well known that tumour morphology, growth pattern and architecture hold important clues 
to differentiating biological subtypes with clinical impact (10). The composition of the tumour 
microenvironment is a key component determining the tumour progression and therapy response (11, 
12). Tumour and non-tumour tissue contribute to image information on the histological slide and to 
the consensus molecular classification (CMS) of CRC at the transcriptional level (13). The CMS 
classification distinguishes four groups of CRC with distinct clinical behaviour and biological 
interpretability. These include CMS1 (14%; microsatellite instability immune, favourable prognosis), 
CMS2 (37%, canonical, epithelial gene expression profile, WNT and MYC signalling activation, 
intermediate prognosis), CMS3 (13%, epithelial profile with evident metabolic dysregulation, 
intermediate prognosis), and CMS4 (23%, mesenchymal, prominent transforming growth factor-β 
activation, poor prognosis) (1, 13). 
CMS subgrouping shows a robust association with targetable alterations and may have potential to 
guide treatment allocation in clinical practice (1, 13). However, clinical implementation of the CMS 
classification has been held back by the considerable costs of RNA sequencing, the inability to 
bioinformatically obtain confident CMS calls from single samples, intratumoural heterogeneity, high 
levels of unclassified calls on biopsies and an unclear performance on FFPE material (13-15). Here, 
we derive a novel image-based CMS (imCMS) classification from H&E-stained tissue sections 
sourced from the Medical Research Council (MRC) and Cancer Research UK (CRUK) Stratification 
in COloRecTal cancer (S:CORT) program and The Cancer Genome Atlas (TCGA). We demonstrate 
the existence of distinct image phenotypes of CRC that reproducibly associate with CMS 
transcriptional classification, key oncogenic driver mutations and prognosis. Automatic, high-fidelity 
classification of three independent clinical cohorts including pre-operative biopsies underlines the 
applicability of this approach to heterogeneous sample sets and relevant clinical settings. We provide 
insight into classification calls for samples with considerable intratumoural heterogeneity and provide 
accurate secondary calls with higher discriminatory power than bioinformatic prediction. In all three 
cohorts, imCMS successfully classified CRC samples that were previously considered to have 
unknown biological and clinical behaviour and failed transcriptional classification. imCMS 
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classification is standardised, inexpensive and could be carried out in a tele-pathology setting on 
routinely available H&E sections. This resolves key issues in the translation of transcriptional 
classification of CRC into clinical practice and has the potential to increase availability of molecular 
stratification in low resource settings.  
MATERIALS AND METHODS 
Study design 
This tudy was designed in accordance with the REMARK guidelines. The study design, cohorts and 
aims are outlined in [Figure 1]. 
Patients 
Cohort 1: FOCUS (Retrospective cohort, S:CORT) 
As part of the Stratification in COloRecTal cancer (S:CORT) program, 385 patients with available 
formalin-fixed paraffin embedded (FFPE) blocks of the primary CRC were selected from the MRC 
FOCUS randomised clinical trial (RCT) that tested different strategies of sequential and combination 
chemotherapy for patients with advanced CRC (30). Serial sections were cut from one representative 
block for H&E staining followed by four unstained sections for RNA extraction, a second H&E and 
eight unstained sections for DNA extraction for a total of 741 slides. H&E slides were re-reviewed by 
expert gastrointestinal pathologists and tumour tissue was annotated and used to guide RNA and 
DNA extractions from the first and second H&E respectively. RNA expression microarrays (Xcel array, 
Affymetrix), DNA target capture (SureSelect, Agilent) followed by NGS sequencing (Illumina) and 
DNA methylation arrays (EPIC arrays, Illumina) were applied in this order. All H&E slides were 
scanned at high resolution on an Aperio scanner at a total magnification of 200X. Digital slides were 
re-reviewed and tumour annotations were traced to generate region annotations for machine learning 
classification. Clinical data was retrieved from the trial database. Pathological TNM-stage and 
sidedness were extracted from pathological reports. Patients with synchronous disease were 
considered to be stage IV. 34 slides with technical failure of the staining or scanning procedure were 
excluded from further analysis. 41 slides had no available RNA expression for CMS classification for 
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a final set of 666 slides (n=362 cases). Clinical and molecular data is summarised in [Table S1] and 
[Figure 1A-B]. 
Cohort 2: TCGA (colon and rectal adenocarcinomas) 
A total of 623 digital slides from 614 cases of colon and rectal adenocarcinoma with available FFPE 
samples were downloaded from the TCGA Data Portal (data accessed on August 2nd, 2018). All 
digital slides were re-reviewed and tumour tissue was annotated. A total of 45 slides were excluded 
based on quality control criteria. Clinical data was obtained from Liu et al (31) while somatic mutations 
and gene level expression data were downloaded with the R package TCGAbiolinks (32) on 
November 7th, 2018. Mutations from Varscan and Mutect were combined and calls for driver 
mutations were computed for relevant genes (all truncating mutations for APC; missense mutations 
for KRAS in codons 12, 13, 19, 22, 59, 61, 68, 117 and 146; V600E for BRAF; all missense and 
truncating mutations for TP53). The final number of slides for imCMS classification was 578 (n=572 
patients) [Table S1] and [Figure 1A-B].  
Cohort 3: GRAMPIAN (Retrospective cohort, S:CORT) 
A total of 323 slides from 183 pre-treatment biopsy FFPE blocks from rectal cancer patients of the 
neoadjuvant setting were available for this study as part of the S:CORT program. All patients received 
pre-operative chemoradiotherapy followed by surgical resection. Slides and molecular profiling were 
processed as described for cohort 1 (FOCUS) but using 5 to 9 sections for RNA extraction and 9 for 
DNA. Pre-operative staging was derived from MRI scans. A total of 14 slides were excluded based 
on quality control criteria for a final set of 309 slides (n = 175 cases). Clinical and molecular data is 
summarised in [Table S1] and [Figure 1A-B].  
Assay methods 
CMS calls 
RNA microarray data was pre-processed and normalised using robust multi-array analysis with the R 
package affy (33) and probes collapsed by mean. CMS calls in all three cohorts were derived with the 
R package CMSclassifier (13) by random forest (RF) with the default posterior probability of 0.5. RF 
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CMS classification of FFPE samples from the FOCUS and GRAMPIAN cohorts led to an increased 
frequency of unclassified samples as compared to the TCGA datasets derived from fresh frozen 
material. In order to derive calls with comparable frequencies, we therefore computed single sample 
predictor calls (R package CMSclassifier) after row-centring the expression data (13). Final CMS calls 
were generated when there was a match between both methods (RF and single sample predictor 
without applying any cut-off). There were 186 TCGA cases (n=191 slides) with discrepancies among 
our CMS calls and the calls originally reported by Guinney et al (13). These discrepant calls are most 
likely the result of the application of a clustering method that is strongly cohort-dependent in our 
analysis based on TCGA samples only and the original report combining thousands of samples from 
several selected cohorts. Due to lack of clear evidence of the ground truth CMS status, samples with 
classification discrepancies were labelled as unclassified.  
Secondary CMS calls from RNA in classified samples were computed by RF using the second highest 
call with posterior probability above 0.3. The primary call was matched if no different CMS subtype 
was found. For unclassified samples, the first highest call above 0.3 was used, leaving the sample as 
unclassified if no subtype met this requirement. All these analyses were performed with R version 
3.5.1 (34). 
CIMP classification 
Methylation array raw data from S:CORT cohorts 1 and 3 was processed with the R-package ChAMP 
(35). CIMP classification was generated by recursively partitioned mixture model as previously done 
in TCGA (36) and Guinney et al (13) with minor changes due to the higher number of probes. CIMP 
classification in TCGA according to Guinney et al was retrieved from Synapse (Synapse ID 
syn2623706).  
imCMS classification 
Pre-processing of image data and exclusion criteria 
For each of the three cohorts, digital slides were re-reviewed and invasive cancer regions were 
annotated by an expert gastrointestinal pathologist using the HALOTM software v2.3.2089.52 (Indica 
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Labs, Corrales, NM, USA). For each slide, the annotated tumour areas were divided into tiles of 
512x512 pixels. To avoid white background regions which did not provide useful information for 
classification, we excluded tiles with less than 50% tissue area. Total tissue area and the number of 
tiles is shown in [Figure S1]. At 5x magnification, consecutive tiles were 50% overlapped in the 
FOCUS and TCGA cohorts (resections). To account for the small sample surface area of the tumour 
identified in the endoscopic biopsies of the GRAMPIAN cohort at 5x, tiles with a 75% overlap were used. 
At 20x, no overlap in FOCUS and TCGA and 50% overlap in GRAMPIAN were used.  
imCMS classifier and the training procedure 
We trained a neural network to classify a given image tile taken from the marked tumour area into 
one of the four CMS classes using supervised learning. Inception V3 (37) pretrained on the ImageNet 
dataset (38) was trained on samples taken from the FOCUS cohort [Figure 1C]. All instances in the 
training set were associated with corresponding molecular data. The class of each tile in the training 
set was matched to the overall RNA-based CMS call of the FOCUS slide. Tiles from unclassified 
slides were excluded. We trained 5 separate models with different subsets of the data in the manner 
akin to cross-validation. The data were split into 5 partitions while preserving the percentage of 
samples for each CMS class. For each model, 3 portions of the data were used for training, one for 
validation, and one for testing. The split was done at the patient level, meaning that no image tiles 
from the same patients would be used for training, validation, and testing at the same time. An 
inception V3 (37) model pretrained on the ImageNet dataset (38) was deployed. We minimised the 
cross-entropy loss of the model on our dataset via gradient backpropagation using Adam optimisation 
(39) with a learning rate of 0.0002 and a batch size of 32 for 100,000 iterations. To prevent the model 
from overfitting, the training image tiles were aggressively augmented using diverse optical and spatial 
transformations implemented in the imgaug library (40). To further avoid the class imbalance problem, 
we also sampled tiles according to the inverse of their class frequencies to guarantee that tiles from 
the minority classes such as CMS3 were sampled frequently in the training process. Finally, we 
selected the state of the model that yields the maximum macro-average AUC on the validation data. 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/645143doi: bioRxiv preprint first posted online May. 23, 2019; 
 
 
9 
 
We implemented the entire imCMS classification framework using the deep learning Pytorch library 
(41). All statistical analyses were performed in R version 3.5.1 (34). 
Testing the model on independent cohorts 
On the TCGA and GRAMPIAN datasets, we applied 5 versions of the, producing 5 different 
classification results for each tile which were then averaged to obtain the final prediction. This is 
analogous to an ensemble of experts’ opinions (27). The prediction probability for each imCMS class 
was obtained from the proportion of the number of tiles assigned to that class, and the final imCMS 
call at the slide level was derived from the majority vote of tiles [Figure 1D]. No unclassified slides 
were used in the evaluation. The classification performance of the model is reported in [Table 2]. 
Domain adversarial training for better generalisation 
To prevent the learning of dataset-dependent features that would limit the general applicability of the 
model we leveraged domain-adversarial training (26). Here the model was augmented with an 
additional classifier for predicting whether image tiles were drawn from training (FOCUS) or external 
cohorts (TCGA and GRAMPIAN) [Figure 1C]. We forced this classifier to perform poorly to encourage 
the model to learn features which are dataset-independent. To train the domain-adversarial classifier, 
all image tiles from the FOCUS cohort and 30% of the tiles from the TCGA and GRAMPIAN datasets 
were used. Domain adversarial training did not involve imCMS class information. Our experiments 
demonstrate domain adversarial learning is critical to train a classifier that is suitable for this task 
[Table 3].  
Adjustment of the imCMS classification probability in the GRAMPIAN cohort 
Image tiles containing histological features associated with the imCMS1 class in resection specimens 
(band like lymphocytic infiltration and mucin) were underrepresented in the rectal biopsies in the 
GRAMPIAN cohort. This resulted in very few biopsy samples considered as imCMS1 with high 
confidence [Table 4] leading us to adjust the slide-level imCMS classification probabilities. To this 
end, we trained a RF classifier (42) with 100 trees of the maximum depth of 2 with 5-fold cross-
validation and only used the results from the test folds to avoid biased adjustment. 
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imCMS classification of the CMS unclassified samples 
CMS unclassified samples from all three cohorts were re-classified using the imCMS classification 
algorithm. To this end, we trained a RF classifier (42) on the imCMS classification probabilities of 
classified samples in the cohort and then applied the learnt classifier to the unclassified samples to 
assign an imCMS call. Note that for the GRAMPIAN cohort, adjustment of the imCMS prediction 
probabilities were required as described in the previous section.  
Intratumoural heterogeneity of the imCMS classification 
Cosine similarity 
To evaluate whether the imCMS classification captures the heterogeneity of the transcriptomic CMS 
classification, we measured the similarity between the imCMS prediction probabilities and their CMS 
counterpart using cosine similarity, i.e. 
𝑐𝑜𝑠𝜃 =
𝑷⋅𝒀
|𝑷||𝒀|
=
∑ 𝑷𝒊𝒀𝒊
𝟒
𝒊=𝟏
√∑ 𝑷𝒊
𝟐𝟒
𝒊=𝟏 √∑ 𝒀𝒊
𝟐𝟒
𝒊=𝟏
 , 
where 𝑃 =  [𝑃1,  𝑃2, 𝑃3, 𝑃4] denotes the imCMS prediction probabilities of a slide, and 𝑌 = [𝑌1, 𝑌2, 𝑌3, 𝑌4] 
represents the CMS classification probabilities from a RF CMSclassifier (13). 
Assessment of the consistency between the imCMS and CMS classification 
heterogeneity 
We assessed whether the level of similarity between the imCMS prediction probabilities and those of 
the transcriptomic CMS was better than the level of similarity produced by a random classifier. 
Samples were stratified according to their primary and secondary CMS profile. For each comparison, 
a total of 100 random predictions were drawn from a 4-dimensional Dirichlet distribution with a 
concentration hyperparameter of 1.0 in each dimension in analogy to the imCMS classification 
probabilities. We calculated the cosine similarities of these random prediction probabilities and the 
mean of the CMS prediction probabilities. 
 
The median difference between groups was compared using the Wilcoxon rank-sum test and the p-
values were adjusted to control false discovery rate (43). Any comparison that was highly 
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underpowered due to the sample size (less than 2 data points in one of the populations) was 
discarded. For each group, outliers were detected via Tukey’s rule (44) and removed. To avoid data 
correlation due to pairs of slides from the same samples, we performed two separate tests in which 
only one slide from a pair is used in each test. P-values <0.05 were considered statistically significant. 
Survival analyses 
Overall survival (OS) in the FOCUS cohort was computed from time of diagnosis of the primary CRC 
(from 1988 to 2003) until death and was right censored for patients still alive at the date of last known 
follow-up. OS and data on the progression-free interval (PFI) in TCGA were retrieved from Liu et al 
(31). Patients with less than 1 month of follow-up were excluded. Survival data for FOCUS and TCGA 
is summarised in [Tables S6, S7, S8 and S9]. The GRAMPIAN cohort was not included in the survival 
analysis due to missing or sparse follow-up data. Univariate Cox proportional hazards analysis was 
performed to assess the prognostic values of the imCMS classification. Multivariable Cox regression 
analysis was carried out with TNM stage, age and gender as possible confounding factors following 
verification of the proportional hazards assumption. P-values <0.05 were considered statistically 
significant. 
Ethics approval 
The use of patient material for cohorts 1 and 3 of the S:CORT program was approved by the ethics 
commission (REC 15/EE/0241).  
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RESULTS 
A deep learning framework for imCMS classification of CRC histology 
slides 
The aim of this study was to develop an image analysis framework to associate features of tissue 
organisation on standard histology slides with molecular classification and outcome data in CRC 
patients. Training and test cohorts were selected to represent relevant clinical scenarios in the 
management of CRC patients including post-operative resection specimens (FOCUS and TCGA) and 
endoscopic biopsy material (GRAMPIAN). A total of 1,553 slides from three independent datasets 
were utilised in this study including 666 slides of resection specimens from 362 patients in the FOCUS 
cohort, 578 slides of resection specimens from 572 patients in the TCGA cohort, and 309 slides from 
pre-operative biopsies of 175 patients in the GRAMPIAN cohort [Figure 1A]. Tumour areas on each 
slide were annotated by a pathologist and the molecular analysis was performed on material obtained 
from strict serial sections to derive the CMS calls (13) [Figure 1B].  
The imCMS classifier was trained against CMS calls on the transcriptionally classified samples of the 
FOCUS cohort and tested on the TCGA and GRAMPIAN cohorts [Online Methods]. With the 
assumption that each CMS class is associated with unique histological patterns localised in different 
regions of the tumours (14), inception V3 deep neural networks (DNN) were trained for prediction of 
CMS calls for small overlapped image regions (tiles) of 512x512 pixels within the annotated regions 
[Figure 1C]. The size distribution of annotated areas per slide and the number of tiles per slide is 
shown in [Figure S1]. The imCMS class, prediction probability and spatial location for each tile were 
recorded. An overall imCMS call for each slide was assigned based on the majority classification of 
tiles [Figure 1D].  
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imCMS classification is accurate, robust and generalisable 
We systematically compared the performance of the imCMS classifier across all three cohorts. For 
benchmarking against molecular data, all unclassified samples were excluded from the test set. 
Classification performance was compared using image tiles derived at a) 5x and b) 20x magnification 
to determine the effect of detail levels. In the FOCUS training cohort, a robust imCMS classification 
performance of 0.88 AUC (macro-average) was reached [Tables 1, S2]. imCMS classification was 
then tested on the unseen TCGA and GRAMPIAN cohorts [Tables 1, S2]. In general, imCMS trained 
at 5x marginally outperformed classification at 20x on whole tissue sections (AUC FOCUS: 0.88 at 5x 
vs 0.87 at 20x; TCGA 0.79 at 5x vs 0.78 at 20x), while the 20x imCMS classifier performed better at 
higher magnification of the endoscopic biopsy specimens (AUC GRAMPIAN: 0.83 at 5x vs 0.85 at 
20x). This suggests that training imCMS at higher magnification supports augmentation of 
morphological features in small tissue samples for imCMS classification. Generalisability was further 
optimised by adversarial domain training of the imCMS framework, which penalises cohort specific-
features during network optimisation [Online Methods]. The optimised classifier reached a final 
classification accuracy of 0.82 AUC on the TCGA cohort and 0.85 AUC on the GRAMPIAN cohort 
[Figure 2A and Table 2]. The correspondence of the CMS and imCMS classification calls for each 
case is shown in [Figures 2B, S2]. Next, we evaluated the consistency of the classification results 
on pairs of slides obtained from the same patients in the FOCUS and GRAMPIAN datasets. Two H&E 
slides were generated at different depth levels of each tissue block with at least 4 additional sections 
cut between for RNA extraction [Figure S3A]. Since tissue features at different tissue levels are 
closely related, a robust classifier would be expected to achieve similar classification results. Indeed, 
imCMS classification achieved consistent prediction probability between the slide pairs across 
different CMS classes (Pearson correlation coefficient, FOCUS: 0.89-0.96 and GRAMPIAN: 0.86-
0.89, Figure S3B). 
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Histological patterns associated with imCMS status 
To understand which specific morphological patterns associate with imCMS, we extracted and visually 
reviewed tiles with the highest prediction confidence for each imCMS subtype. The large-scale 
histology patterns corresponded well with the biological characteristics of the CMS1 and CMS4 
classes as predicted from the molecular assay (13): Mucinous differentiation and lymphocytic 
infiltration were associated with imCMS1, and a prominent desmoplastic stromal reaction with 
imCMS4. imCMS further allowed to visualise and systematically compare the previously poorly 
defined histological patterns of CMS2 and CMS3 classes. Image tiles associated with high confidence 
calls of imCMS2 and imCMS3 showed a predominantly glandular differentiation [Figures 2C, S4A]. 
In imCMS2, evident cribriform growth patterns and comedo-like necrosis was observed, while 
imCMS3 was characterised by ectatic, mucin filled glandular structures in combination with a minor 
component showing papillary and cribriform morphology. Detailed visualisation of the image 
representations at the pixel-level corroborated the cellular and tissue components that weigh in on 
imCMS at high resolution [Figure S4B].  
imCMS classification on molecularly unclassified CMS samples 
Failure of the transcriptional CMS classification might represent a transition phenotype, intratumoural 
heterogeneity or might represent technical failure to classify (13). We therefore tested the 
performance of imCMS in samples categorised as unclassifiable by transcriptomic CMS [Figure 2B]. 
As compared to transcriptional classification, imCMS yielded a significantly higher prediction 
confidence on the molecularly unclassified samples [Figure S5]. Successful re-classification is 
underlined by a direct comparison of the key molecular profiles between classified samples and the 
imCMS reclassified samples. No major differences between these two groups in the majority of the 
traits except for CMS1 was found [Figures 2D, S6, and Table S2]. However, within the CMS1 
subgroup, MSI samples were characterised by higher a priori RF CMS prediction scores (0.69 in MSI+ 
vs 0.51 in MSI-, p=2x10-16, Student’s t-test), leading to a higher probability of accurate identification 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/645143doi: bioRxiv preprint first posted online May. 23, 2019; 
 
 
15 
 
by CMS. This skewed the proportion of the remaining unclassified samples within the CMS1 subgroup 
by transcriptional classification towards MSS CRC and explains differences in distribution of MSI-
associated molecular features (BRAF, KRAS, CIMP) between the classified and unclassified 
samples.  
Intratumoural heterogeneity of the imCMS classification 
CRC tumours exhibit intratumoural variability in transcriptional features leading to a bias in 
transcriptional CMS calls introduced by the regions sampled for molecular analysis (14). imCMS 
captures this intrinsic variation in separate predictions for each image tile and provides a model to 
better reflect and visualise the intratumoural transcriptional heterogeneity of CRC [Figures 3A, S7a-
d]. We investigated if imCMS heterogeneity was associated with that of the molecular classification. 
Comparison of the imCMS versus CMS prediction probabilities revealed a high level of agreement 
between both classification schemes in the majority of the slides [Figures 3B, S8A]. We next derived 
secondary CMS calls from the molecular data [Figure 3C, Online Methods] and further looked at 
the similarity between the corresponding CMS and imCMS prediction probabilities as stratified by 
primary and secondary CMS calls [Figure 3D]. Based on the cosine similarity measure, the match in 
the variation of the prediction scores was significantly better than by random chance in the majority 
of groups [Figures 3D, S8b, Online Methods], underlining the potential of imCMS to detect and 
spatially resolve intratumoural heterogeneity in the transcriptional classification of CRC. 
Prognostic associations by imCMS status 
We performed univariate Cox proportional hazard analysis to assess the prognostic value of the 
imCMS classification as compared to its molecular counterpart. In the FOCUS cohort, patient survival 
outcomes stratified by imCMS classification were highly in agreement with those of the transcriptional 
classification [Figure 4A and Tables S6, S7]. The prognostic association of the imCMS classification 
was maintained in multivariate analysis including TNM stage, age and gender, indicating strong 
potential to stratify risk beyond pathological staging [Table 5]. imCMS survival predictions were 
concordant when the input slides were replaced by sections cut at deeper tissue levels [Table S3 
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and Figure S9A]. For the TCGA cohort, PFI by both imCMS and CMS groups was highly consistent 
with CMS4 having the poorest prognosis [Figure 4B and Table S4]. For OS, the CMS4 group was 
associated with the worst outcome while imCMS linked the imCMS1 group to adverse outcome 
[Figure 4B and Table S4]. This discrepancy in the TCGA cohort could be explained by a less robust 
representation of disease biology by OS as compared to PFI but requires additional investigation in 
subsequent studies. We further explored the application of the imCMS classification for risk 
stratification in the unclassified samples of the TCGA cohort. In this previously unclassified group, the 
imCMS4 group was shown to have worse prognosis for both OS and PFI [Figure S9b and Table S5].  
DISCUSSION 
H&E slides are generated as part of the standard work-up of any CRC treated by surgical resection 
(16, 17). In the assessment of this histologic material, pathologists are presently limited to the strictly 
defined set of morphologic and anatomic criteria (16, 17). This information supports the definition of 
broad prognostic risk groups but has no predictive value (16). The integration of genomic technologies 
in the clinical care of CRC patients has immense potential to drive personalised treatment but requires 
substantial financial, personnel and infrastructure resources (18). Combining morphological and 
molecular pathology to identify genotype-phenotype correlations is a promising approach to extend 
the amount of clinically relevant information that can be extracted from standard histologic slides (8). 
In this study, we leverage artificial intelligence and image analysis technologies for the development 
of an image-based taxonomy of CRC with clear biological interpretability and clinical impact. Due to 
general applicability and low costs, morphomolecular classification of histopathology slides could 
become a new standard for patient stratification in clinical practice.  
We trained and tested our image-based approach towards consensus molecular subtyping (imCMS) 
of CRC on three independent and well-characterised patient cohorts with availability of digital slides 
and transcriptional information from the CRUK MRC S:CORT program and TCGA. We specifically 
focused on relevant clinical scenarios in the management of CRC patients and investigated the 
imCMS classification of both preoperative biopsies and resection specimens. Our analyses 
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demonstrate that the imCMS classifier is able to predict the consensus molecular signatures of CRC 
from histological slides with very high accuracy. While tissue features captured at low magnification 
proved most informative on CRC resection specimens, imCMS could be efficiently adapted for 
morpho-molecular classification of rectal cancer biopsy fragments at high magnification. Small biopsy 
fragments have previously proven difficult to analyse using genomic technologies due to the limited 
amount of tissue available (19). Pathologist assessment is therefore usually restricted to the diagnosis 
of cancer, a select panel of immunohistochemical studies and a limited assessment of additional 
prognostic features (17, 20). Clinically approved assays that are predictive of therapeutic response 
from biopsy material are presently lacking, with up to 25% of rectal cancer patients gaining no benefit 
from current radiotherapy and chemotherapy protocols (21). As a stemlike (CMS4) transcriptional 
profile of CRC has been linked to poor prognosis and therapeutic resistance, imCMS could allow for 
more effective stratification of patients for primary surgery or neoadjuvant treatment (22, 23). 
Prospective studies are warranted to investigate the application of imCMS as a novel clinical 
stratification tool. 
Our analysis demonstrates the feasibility of imCMS classification of both primary colon and rectal 
resection specimens in the FOCUS and TCGA cohorts. imCMS calls closely matched transcriptional 
classification for survival stratification, underlining the strong potential of imCMS for translation into 
the clinical routine. imCMS classification of surgically treated primary CRC could aid pathologists in 
the identification of aggressive disease for intensified follow-up and chemotherapy trials (1). In 
advanced disease, the development of molecular stratifiers for the prediction of treatment response 
is of critical importance to balance care and overtreatment. No clinically approved tests are currently 
available to predict chemotherapy response in metastatic CRC with as many as 20 patients 
statistically needed to receive the combination treatment with 5-Fluorouracil and Oxaliplatin to achieve 
long term (>3 year) disease free survival for one individual (22). Beneficial effects are set off by 
considerable toxicity including debilitating chronic peripheral neuropathy in up to 50% of cases (24). 
Transcriptional classification of CRC has shown promise to stratify survival outcomes and response 
to treatment in retrospective analyses but requires further validation (22, 23). imCMS represents a 
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readily translatable and cost-effective approach for further investigation of treatment outcomes in 
existing retrospective cohorts and future clinical trials.  
Limited generalisability of image analysis algorithms is a well-recognised problem in the setting of 
limited training sets and poorly annotated ground truth data (25). We addressed the problem of 
sample diversity by training the imCMS classifier on histological samples sourced from multiple 
institutes (n=59) participating in the FOCUS trial. Domain adversarial training was used to minimise 
the classification weight of cohort dependent features in the final models (26). The ensemble of 
multiple models, analogous to consensus of experts’ opinions reduces the bias of individual 
predictions (27). High-level annotations were guaranteed by a strict protocol where each H&E section 
used for digital image analysis was followed by slides cut for molecular profiling with precisely 
matched annotations. This allowed us to directly associate transcriptional signatures with histological 
phenotypes in CRC at unprecedented resolution. RNA expression signatures represent both tumour 
intrinsic and microenvironment related signals which are intimately linked to CRC phenotypes with 
distinct biological characteristics and disease outcomes (1, 13). imCMS highlighted the well-known 
morpho-molecular associations with inflammatory infiltrates (imCMS1) and a prominent stromal 
reaction (imCMS4) but also identified novel morphological features in association with high-
confidence calls of imCMS2 and imCMS3 while robustly reproducing the known molecular 
associations of transcriptionally derived CMS subtypes. Our study underlines that convolutional 
neural networks excel in their ability to learn relationships of tissue compartments as a whole and to 
identify relevant patterns with clear morphological interpretability.  
Transcriptomic CMS was released as the most robust molecular classification in CRC and the basis 
for clinical stratification and targeted intervention (1, 13). However, some key issues hamper clinical 
implementation of CMS such as the inability to obtain reliable calls from single samples. Two methods 
to call CMS were released by the original authors based on RF and single sample prediction (13). 
The former provides reliable classification but is cohort-dependent and requires a high minimum 
number of samples while the latter generates calls on single samples with limited quality leading to 
underutilisation. Another problem is that some samples do not show enough evidence to make calls 
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by either method leading to a substantial number of cases left as unclassified. Inconsistent 
classification calls could also be an expression of intratumoural heterogeneity or representative of a 
transition phenotype which is of considerable biological interest (1, 13). Spatial heterogeneity is an 
additional confounder that can result in CMS misclassification (14). imCMS is able to overcome all 
these problems. imCMS calls are intrinsically generated for single samples. Notably, imCMS images 
visualise heterogeneity through tile-based classification calls with a cell size of 512 x 512 pixels, 
allowing us to derive quantitative prediction scores with biological interpretability. Here, we show that 
transcriptionally unclassified samples tend to have higher heterogeneity of the image-based 
classification results as compared to the CMS classified samples. Importantly, all CMS unclassified 
samples were successfully reclassified by imCMS and their molecular characteristics as well as 
survival profiles closely resembled those classified by sequencing methods. These results suggest 
that imCMS performs reliably in samples categorised as unclassified by transcriptional profiling and 
indicates that different molecular profiles within CMS subgroups may be biological rather than 
technical. Re-classification by imCMS achieved significantly higher confidence for sample 
categorisation than transcriptional profiling. To further investigate sample heterogeneity, we 
bioinformatically derived secondary CMS calls from all samples and investigated the similarity of the 
CMS and imCMS prediction probabilities for primary and secondary calls. imCMS captured secondary 
calls with high accuracy based on a cosine similarity measure between transcriptional and image-
based classification. Taken together, imCMS allows for the first time to localise sources of 
heterogeneity on the original tissue slide and to understand, control and further investigate sources 
of heterogeneity in the transcriptional classification of CRC. In addition, imCMS is a versatile tool to 
address deficiencies in transcriptional profiling that may arise due to low amounts or quality of RNA, 
an expected problem in clinical FFPE blocks.  
With this paper we demonstrate that it is possible to identify CMS on the basis of tissue morphology. 
The possibility of identifying morphological correlates that are associated with molecular subtypes 
opens new opportunities for in vitro diagnostics. However, the application of image-based patient 
stratification is presently limited by the availability of digital pathology infrastructure in routine 
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diagnostic practice. This is met by broad scale initiatives for digitalization of medical infrastructure on 
a national and international level (28, 29). Centralized testing could further compensate for the 
availability of computing infrastructure in low resource settings. Prospective validation of imCMS in 
independent studies will be critical to clinical translation. This includes both applications as a tool that 
could rationalize which cases would need confirmatory testing as well as stand-alone testing in cases 
where genomic methods fail to provide reliable classification. We hypothesise that the general 
principle can be applied not only to other cancer types but also to other diseases. It will therefore lay 
the foundation of a more systematic integration of image-based morphological analysis and molecular 
stratification.  
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FIGURES AND FIGURE LEGENDS 
Figure 1: Data, study design, and imCMS classification framework.  
 
Figure 1, legend: Three independent datasets (FOCUS, TCGA, and GRAMPIAN) were used 
in this study. (A) The distribution of the samples stratified by the CMS calls in each dataset. 
(B) The FOCUS dataset was primarily used for learning the imCMS discriminative model 
while the TCGA and GRAMPIAN datasets were used for testing. (C) Training of the imCMS 
discriminative model based on the domain-adversarial approach. Image tiles were extracted 
from annotated tumour regions. Tiles from the FOCUS cohort were categorised by CMS class 
of the original slide and were used to train the model to predict the imCMS classes on unseen 
datasets. Tiles from the TCGA and GRAMPIAN cohorts were unlabelled and were used 
together with those from the FOCUS cohort in the cohort (domain) prediction. Domain-
adversarial training forced the cohort classifier to perform poorly which in turn encouraged 
the model to learn indiscriminative features across datasets. Five distinct models were 
produced. (D) At the inference time, the ensemble of the learnt models predicts the imCMS 
class for each of the image tiles extracted from annotated tumor regions of a slide. A slide is 
assigned to the imCMS class with the maximum prediction score (i.e. highest number of tiles 
in the slide). 
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Figure 2: image-based consensus molecular subtype classification. 
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Figure 2, legend: (A) Receiver operating curves (ROC) of the imCMS classifier, optimised 
by the domain adversarial approach, on the FOCUS (n slides = 506, 5x), TCGA (n slides = 
366, 5x), and GRAMPIAN cohorts (n slides = 205, 20x). (B) Correspondences between CMS 
and imCMS classes in different datasets. All samples labeled as unclassified by RNA-based 
CMS calls were successfully re-classified by imCMS (C) Examples of image tiles with high 
prediction confidence for each imCMS class in FOCUS. Histological patterns associated with 
imCMS 1 are mucin and lymphocytic infiltration. In imCMS2, evident cribriform growth 
patterns and comedo-like necrosis are observed, while imCMS3 is characterised by ectatic, 
mucin filled glandular structures in combination with a minor component showing papillary 
and cribriform morphology. imCMS4 are predominantly associated with infiltrative CRC 
growth pattern, a prominent desmoplastic stromal reaction and frequent presence of single 
cell invasion (tumor budding). Scale bar ~ 1 mm. (D) Molecular associations of the CMS 
classified samples (black) and the CMS unclassified samples that have been classified by 
imCMS (grey). The molecular profiles of reclassified samples are largely consistent with 
those of the classified CMS samples. Statistically significant differences (p < 0.05) are marked 
with a red asterisk. 
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Figure 3: Intratumoural heterogeneity of the imCMS molecular subtypes. 
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Figure 3, legend: (A) Visualisation of the regional classification of the imCMS classifier. 
imCMS classification of a tumour sample can exhibit uniform results (left) or a degree of 
variation in the predicted imCMS class and the level of confidence (right). The colour overlay 
indicates the imCMS classes and the opacity reflects the classification confidence. (B) 
Heterogeneity of the CMS and imCMS classification at the slide level. Each bar represents 
classification probabilities of a sample. (C) Heterogeneity of the CMS classification. A 
secondary CMS call was derived by relaxing the classification threshold of the random forest 
CMS classifier (13). (D) Cosine similarity between the imCMS and CMS prediction scores, 
stratified by the primary and secondary CMS calls. The levels of similarity were compared 
against those produced by a random classifier. Statistical analysis was performed using 
Wilcoxon rank-sum test, adjusted for the false discovery rate.  P-value < 0.05 was considered 
statistically significant. 
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Figure 4: Prognostic associations of the image-based consensus 
molecular subtypes. 
 
 
 
 
Figure 4, legend: Overall survival (OS) and progression-free survival (PFS) outcomes of the 
(A) FOCUS cohort (n=276 cases) and (B) TCGA (OS n=346 cases, PFS n = 342 cases) as 
stratified by the transcriptional-based CMS classification and image-based CMS 
classification. Kaplan-Meier estimator was used to estimate the survival probability, and 
pairwise log-rank test and univariate Cox proportional hazards regression were performed 
between CMS groups and imCMS groups. Hazard ratios (HR) and 95% confidence interval 
(95% CI) for pairwise comparisons were reported. Test results with p-value < 0.05 were 
considered statistically significant. 
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Supplementary Figures S1-S9 
Figure S1: Slide statistics.  
 
Figure S1, legend: (A) The distribution of annotated tumour areas in different datasets. (E) 
The distribution of the number of tiles extracted from the annotated regions at 5x and 20x. 
 
Figure S2: imCMS classification.  
 
Figure S2, legend: Confusion matrices showing the classification performance of the 
imCMS model on different datasets. A sample is assigned to the imCMS class with the 
maximum prediction score (i.e. highest number of tiles in the slide).  
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Figure S3: Consistency of the prediction probability.  
 
 
Figure S3, legend: (A) Examples of pairs of slides from the FOCUS and GRAMPIAN 
datasets. (B) Pearson correlation coefficient of the predicted probabilities between pairs of 
slides. 
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Figure S4 Morphological correlates of the imCMS classes. 
 
Figure S4, legend: (A) Example image tiles with high prediction confidence from the TCGA 
cohort (scale bar ~ 1 mm) and the GRAMPIAN cohort (scale bar ~ 255 microns). (B) Pixel 
locations important for the class decision are highlighted. The order of importance is 
represented as a gradient between green and red, where red indicates the highest level of 
importance. The highlighted pixel locations correspond largely to lymphocyte and mucin in 
imCMS1, tumour areas in imCMS2 and imCMS3, and infiltrative tumour front and stroma in 
imCMS4.  
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Figure S5: Comparison of the prediction confidences of the CMS and 
imCMS classifiers in the CMS unclassified samples.  
 
Figure S5, legend: (A) Correspondences between the top CMS and imCMS prediction 
scores. (B) The top imCMS prediction scores are significantly higher than the 
corresponding CMS prediction scores in all datasets (Wilcoxon signed rank test, p-values < 
0.05). (C) The differences between the top and the second top prediction scores produced 
by the imCMS classifier are significantly larger their CMS counterparts (Wilcoxon signed 
rank test, p-values < 0.05). 
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Figure S6: imCMS classification of the CMS unclassified samples. 
 
Figure S6, legend: Molecular associations based on the 2nd slide of the CMS classified 
samples (black) and the CMS unclassified samples that have been classified by imCMS 
(grey). A significantly different profile (p < 0.05) is marked with a red asterisk. 
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Figure S7: Intratumoural heterogeneity of the imCMS prediction. 
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Figure S7, legend: The heterogeneity of the imCMS prediction per slide can be observed 
both in the form of the variation in the predicted classes and the variation in the levels of the 
prediction confidence. (A) CMS classified samples with a low level of imCMS prediction 
heterogeneity. (B) CMS classified samples with a high level of imCMS prediction 
heterogeneity. (C) CMS unclassified samples with a low level of imCMS prediction 
heterogeneity. (D) CMS unclassified samples with a high level of imCMS prediction 
heterogeneity. 
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Figure S8: Intratumoural heterogeneity of the imCMS prediction (2nd 
slides).  
 
 
Figure S8, legend: (A) Heterogeneity of the CMS and imCMS classifications. Each bar 
represents classification probabilities of a sample. (B) Cosine similarity between the imCMS 
and CMS prediction scores, stratified by the primary and the secondary CMS calls. The 
levels of similarity were compared against those produced by a random classifier. Statistical 
analysis was performed using Wilcoxon rank-sum test, adjusted for the false discovery rate.  
P-value < 0.05 was considered statistically significant. 
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Figure S9: Prognostic associations of the imCMS classification.  
 
 
Figure S9, legend: (A) Overall survival analysis based on the 2nd slides of the FOCUS 
cohort (n=276). (B) survival outcomes of the unclassified samples (n=196 cases) from 
TCGA cohort as stratified by imCMS classification. 
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TABLES AND TABLE LEGENDS 
Table 1: Area under the curve (AUC) with 95% confidence intervals achieved by the imCMS classifier. 
 
CMS class 
 
FOCUS 
n slides = 506  
n patients = 276 
TCGA  
n slides = 366  
n patients = 365 
GRAMPIAN 
n slides = 205 
n patients = 114  
5x 20x 5x 20x 5x 20x 
CMS1 0.85 (0.8,0.89) 0.85 (0.81,0.89) 0.8 (0.73,0.87) 0.8 (0.75,0.88) 0.73 (0.6,0.9) 0.79 (0.72,0.87) 
CMS2 0.88 (0.86,0.91) 0.86 (0.83,0.91) 0.79 (0.74,0.83) 0.79 (0.75,0.83) 0.76 (0.69,0.83) 0.76 (0.7,0.83) 
CMS3 0.92 (0.9,0.96) 0.9 (0.85,0.94) 0.77 (0.68,0.88) 0.74 (0.65,0.82) 0.81 (0.74,0.89) 0.85 (0.78,0.92) 
CMS4 0.86 (0.83,0.9) 0.85 (0.82,0.89) 0.78 (0.72,0.86) 0.77 (0.72,0.82) 0.92 (0.87,0.99) 0.92 (0.88,1) 
Macro-average 0.88 (0.86,0.9) 0.87 (0.84,0.89) 0.79 (0.75,0.83) 0.78 (0.74,0.81) 0.81 (0.76,0.85) 0.83 (0.79,0.88) 
Micro-average 0.89 (0.88,0.91) 0.88 (0.86,0.91) 0.77 (0.74,0.8) 0.77 (0.73,0.81) 0.83 (0.8,0.87) 0.85 (0.81,0.89) 
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Table 2: Area under the curve (AUC) with 95% confidence intervals achieved by the imCMS classifier.  
 
A) FOCUS 
CMS 
5x (FOCUS, n slides = 506, n patients = 276)  
Model 1 Model 2 Model 3 Model 4 Model 5 Overall 
CMS1 0.86 (0.76,0.97) 0.85 (0.73,0.97) 0.94 (0.9,0.99) 0.83 (0.74,0.92) 0.75 (0.64,0.93) 0.85 (0.8,0.89) 
CMS2 0.88 (0.82,0.96) 0.93 (0.89,0.98) 0.95 (0.92,0.99) 0.84 (0.77,0.94) 0.83 (0.75,0.93) 0.88 (0.86,0.91) 
CMS3 0.93 (0.87,1) 0.97 (0.94,1.01) 0.92 (0.86,0.99) 0.9 (0.83,0.99) 0.92 (0.84,1.02) 0.92 (0.9,0.96) 
CMS4 0.9 (0.85,0.97) 0.82 (0.75,0.93) 0.84 (0.73,0.99) 0.88 (0.81,1) 0.88 (0.81,0.98) 0.86 (0.83,0.9) 
Macro-average 0.89 (0.84,0.94) 0.89 (0.84,0.93) 0.91 (0.87,0.96) 0.86 (0.81,0.92) 0.84 (0.79,0.91) 0.88 (0.86,0.9) 
Micro-average 0.9 (0.86,0.95) 0.9 (0.86,0.96) 0.92 (0.89,0.96) 0.88 (0.83,0.93) 0.86 (0.81,0.91) 0.89 (0.88,0.91) 
 
 
CMS 
20x (FOCUS, n slides = 506, n patients = 276) 
Model 1 Model 2 Model 3 Model 4 Model 5 Overall 
CMS1 0.89 (0.81,0.99) 0.85 (0.76,0.95) 0.9 (0.84,1.02) 0.89 (0.83,0.97) 0.74 (0.6,0.89) 0.85 (0.81,0.89) 
CMS2 0.89 (0.83,0.96) 0.92 (0.87,0.97) 0.89 (0.83,0.95) 0.84 (0.78,0.93) 0.84 (0.76,0.92) 0.86 (0.83,0.91) 
CMS3 0.93 (0.88,0.99) 0.92 (0.86,0.99) 0.82 (0.66,1.04) 0.89 (0.82,0.97) 0.95 (0.92,1.01) 0.9 (0.85,0.94) 
CMS4 0.9 (0.85,0.96) 0.86 (0.8,0.95) 0.84 (0.76,0.96) 0.89 (0.82,0.97) 0.81 (0.74,0.92) 0.85 (0.82,0.89) 
Macro-average 0.9 (0.86,0.95) 0.89 (0.85,0.93) 0.86 (0.8,0.93) 0.88 (0.83,0.93) 0.84 (0.78,0.89) 0.87 (0.84,0.89) 
Micro-average 0.9 (0.86,0.95) 0.9 (0.87,0.94) 0.89 (0.85,0.94) 0.87 (0.82,0.92) 0.83 (0.79,0.89) 0.88 (0.86,0.91) 
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B) TCGA 
CMS 
5x (TCGA, n slides = 366, n patients  = 365) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble model 
CMS1 0.83 (0.77,0.89) 0.78 (0.72,0.85) 0.76 (0.69,0.85) 0.79 (0.72,0.86) 0.75 (0.69,0.81) 0.8 (0.73,0.87) 
CMS2 0.78 (0.73,0.83) 0.72 (0.67,0.78) 0.76 (0.71,0.81) 0.72 (0.66,0.78) 0.74 (0.7,0.81) 0.79 (0.74,0.83) 
CMS3 0.76 (0.69,0.84) 0.71 (0.63,0.83) 0.7 (0.61,0.8) 0.78 (0.71,0.85) 0.75 (0.66,0.83) 0.77 (0.68,0.88) 
CMS4 0.76 (0.7,0.81) 0.76 (0.7,0.82) 0.78 (0.72,0.82) 0.75 (0.69,0.81) 0.71 (0.64,0.77) 0.78 (0.72,0.86) 
Macro-average 0.78 (0.75,0.81) 0.74 (0.72,0.78) 0.75 (0.7,0.79) 0.76 (0.73,0.79) 0.74 (0.69,0.78) 0.79 (0.75,0.83) 
Micro-average 0.79 (0.75,0.82) 0.72 (0.68,0.76) 0.75 (0.72,0.79) 0.7 (0.66,0.74) 0.73 (0.69,0.76) 0.77 (0.74,0.8) 
 
 
CMS 
20x (TCGA, n slides = 366, n patients  = 365) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble model 
CMS1 0.8 (0.75,0.88) 0.76 (0.68,0.83) 0.76 (0.68,0.83) 0.8 (0.74,0.88) 0.74 (0.68,0.82) 0.8 (0.75,0.88) 
CMS2 0.75 (0.7,0.81) 0.76 (0.7,0.81) 0.75 (0.7,0.8) 0.75 (0.7,0.8) 0.75 (0.7,0.8) 0.79 (0.75,0.83) 
CMS3 0.73 (0.66,0.84) 0.63 (0.53,0.75) 0.71 (0.63,0.8) 0.7 (0.61,0.81) 0.77 (0.7,0.88) 0.74 (0.65,0.82) 
CMS4 0.71 (0.65,0.8) 0.73 (0.67,0.79) 0.73 (0.68,0.79) 0.75 (0.69,0.84) 0.73 (0.69,0.8) 0.77 (0.72,0.82) 
Macro-average 0.75 (0.72,0.78) 0.72 (0.68,0.76) 0.74 (0.7,0.78) 0.75 (0.72,0.78) 0.75 (0.71,0.78) 0.78 (0.74,0.81) 
Micro-average 0.75 (0.71,0.8) 0.73 (0.7,0.76) 0.75 (0.71,0.78) 0.71 (0.67,0.75) 0.76 (0.73,0.8) 0.77 0.73,0.81) 
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C) GRAMPIAN 
CMS 
5x (n slides= 205, n patients = 114) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble model 
CMS1 0.75 (0.62,0.9) 0.69 (0.57,0.81) 0.65 (0.53,0.78) 0.67 (0.54,0.81) 0.66 (0.48,0.76) 0.73 (0.6,0.9) 
CMS2 0.7 (0.64,0.78) 0.64 (0.56,0.73) 0.74 (0.66,0.81) 0.65 (0.57,0.74) 0.79 (0.74,0.87) 0.76 (0.69,0.83) 
CMS3 0.75 (0.67,0.85) 0.73 (0.64,0.83) 0.7 (0.62,0.82) 0.81 (0.75,0.89) 0.81 (0.74,0.89) 0.81 (0.74,0.89) 
CMS4 0.9 (0.85,0.94) 0.9 (0.85,0.98) 0.91 (0.86,0.96) 0.78 (0.67,0.9) 0.88 (0.82,0.96) 0.92 (0.87,0.99) 
Macro-average 0.77 (0.72,0.82) 0.74 (0.69,0.8) 0.75 (0.69,0.8) 0.73 (0.67,0.79) 0.79 (0.73,0.83) 0.81 (0.76,0.85) 
Micro-average 0.8 (0.75,0.85) 0.76 (0.71,0.8) 0.79 (0.75,0.84) 0.72 (0.68,0.77) 0.81 (0.77,0.86) 0.83 (0.8,0.87) 
 
 
CMS 
20x (n slides= 205, n patients = 114) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble model 
CMS1 0.8 (0.71,0.91) 0.71 (0.64,0.78) 0.72 (0.62,0.82) 0.81 (0.73,0.9) 0.63 (0.49,0.75) 0.79 (0.72,0.87) 
CMS2 0.78 (0.72,0.85) 0.61 (0.52,0.71) 0.71 (0.61,0.8) 0.66 (0.57,0.75) 0.72 (0.66,0.8) 0.76 (0.7,0.83) 
CMS3 0.87 (0.82,0.93) 0.53 (0.43,0.61) 0.85 (0.78,0.93) 0.85 (0.81,0.91) 0.79 (0.73,0.87) 0.85 (0.78,0.92) 
CMS4 0.93 (0.89,0.97) 0.86 (0.79,0.94) 0.87 (0.8,0.97) 0.84 (0.76,0.94) 0.92 (0.87,0.98) 0.92 (0.88,1) 
Macro-average 0.84 (0.81,0.88) 0.68 (0.62,0.71) 0.79 (0.74,0.85) 0.79 (0.74,0.83) 0.76 (0.71,0.8) 0.83 (0.79,0.88) 
Micro-average 0.86 (0.82,0.91) 0.61 (0.56,0.66) 0.82 (0.78,0.86) 0.75 (0.71,0.8) 0.78 (0.74,0.84) 0.85 (0.81,0.89) 
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Table 3: Area under the curve (AUC) with 95% confidence intervals achieved by the imCMS classifier 
trained by domain-adversarial training. 
 
A) FOCUS 
CMS 
5x (n slides = 506, n patients = 276) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble 
CMS1 0.87 (0.78,0.96) 0.84 (0.73,1.04) 0.95 (0.91,1) 0.81 (0.7,0.93) 0.75 (0.63,0.89) 0.84 (0.81,0.88) 
CMS2 0.89 (0.83,0.96) 0.95 (0.92,1.01) 0.94 (0.91,0.99) 0.88 (0.82,0.96) 0.83 (0.75,0.93) 0.89 (0.86,0.92) 
CMS3 0.94 (0.89,0.99) 0.98 (0.96,1.01) 0.89 (0.8,1.02) 0.85 (0.76,1) 0.94 (0.9,1) 0.92 (0.89,0.95) 
CMS4 0.89 (0.83,0.99) 0.89 (0.82,0.96) 0.8 (0.69,0.95) 0.9 (0.84,0.98) 0.84 (0.77,0.93) 0.85 (0.81,0.88) 
Macro-average 0.89 (0.85,0.94) 0.91 (0.87,0.95) 0.89 (0.83,0.96) 0.86 (0.8,0.93) 0.84 (0.77,0.91) 0.88 (0.86,0.9) 
Micro-average 0.88 (0.83,0.92) 0.92 (0.88,0.97) 0.91 (0.87,0.95) 0.88 (0.84,0.93) 0.83 (0.79,0.87) 0.88 (0.87,0.91) 
 
 
B) TCGA 
CMS 
5x (n slides = 366, n patients = 365) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble 
CMS1 0.84 (0.79,0.91) 0.83 (0.78,0.87) 0.81 (0.75,0.88) 0.81 (0.75,0.89) 0.81 (0.75,0.86) 0.84 (0.79,0.89) 
CMS2 0.79 (0.74,0.84) 0.81 (0.77,0.87) 0.79 (0.74,0.85) 0.8 (0.76,0.86) 0.79 (0.74,0.85) 0.83 (0.78,0.87) 
CMS3 0.82 (0.76,0.89) 0.75 (0.68,0.83) 0.8 (0.73,0.87) 0.81 (0.73,0.9) 0.82 (0.75,0.9) 0.83 (0.76,0.9) 
CMS4 0.73 (0.68,0.8) 0.77 (0.73,0.83) 0.74 (0.7,0.8) 0.78 (0.73,0.84) 0.72 (0.67,0.78) 0.78 (0.72,0.83) 
Macro-average 0.8 (0.76,0.83) 0.79 (0.76,0.83) 0.79 (0.75,0.82) 0.8 (0.77,0.84) 0.79 (0.75,0.82) 0.82 (0.79,0.85) 
Micro-average 0.81 (0.78,0.85) 0.8 (0.77,0.83) 0.8 (0.78,0.84) 0.81 (0.77,0.85) 0.79 (0.77,0.83) 0.83 (0.8,0.86) 
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C) GRAMPIAN 
CMS 
20x (n slides = 205, n patients = 114) 
Model 1 Model 2 Model 3 Model 4 Model 5 Ensemble 
CMS1 0.81 (0.73,0.9) 0.56 (0.41,0.72) 0.74 (0.61,0.85) 0.77 (0.66,0.89) 0.85 (0.78,0.96) 0.85 (0.78,0.91) 
CMS2 0.83 (0.77,0.89) 0.75 (0.67,0.83) 0.74 (0.66,0.8) 0.7 (0.62,0.78) 0.79 (0.74,0.85) 0.8 (0.74,0.85) 
CMS3 0.89 (0.83,0.96) 0.8 (0.73,0.89) 0.8 (0.71,0.89) 0.8 (0.73,0.87) 0.82 (0.76,0.88) 0.86 (0.8,0.93) 
CMS4 0.91 (0.87,0.96) 0.84 (0.75,0.93) 0.86 (0.79,0.93) 0.9 (0.84,0.97) 0.91 (0.87,0.98) 0.92 (0.86,0.99) 
Macro-average 0.86 (0.82,0.9) 0.74 (0.68,0.79) 0.79 (0.73,0.84) 0.79 (0.74,0.83) 0.84 (0.81,0.89) 0.85 (0.82,0.89) 
Micro-average 0.86 (0.83,0.91) 0.78 (0.74,0.84) 0.79 (0.75,0.84) 0.81 (0.76,0.86) 0.84 (0.81,0.88) 0.84 (0.8,0.89) 
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Table 4: Percentages of image tiles classified as different imCMS classes 
 
Prediction 
FOCUS TCGA GRAMPIAN 
n tiles = 410481 n tiles = 93161 n tiles = 43754 
imCMS1 25% 20% 4% 
imCMS2 31% 49% 55% 
imCMS3 11% 15% 26% 
imCMS4 33% 16% 15% 
 
 
Table 5: Multivariate Cox proportional hazards regression on classified samples of the FOCUS cohort 
 
FOCUS (n patients=263) Multivariate survival analysis (adjusted by gender, age, T, N, M) 
Variable HR 95%CI Low 95%CI High p-value 
CMS1 vs CMS2 2.60 1.68 4.02 1.72E-05 
CMS3 vs CMS2 0.98 0.62 1.54 9.18E-01 
CMS4 vs CMS2 1.34 0.93 1.91 1.12E-01 
imCMS1 vs imCMS2 2.20 1.37 3.54 1.13E-03 
imCMS3 vs imCMS2 1.37 0.86 2.17 1.89E-01 
imCMS4 vs imCMS2 1.48 1.05 2.08 2.68E-02 
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Supplementary Tables S1-S5  
 
Please see separate datafiles 
Table S1: Clinicopathological and molecular associations of the datasets 
(FOCUS, TCGA, GRAMPIAN) 
Table S2: Molecular associations of CMS classified samples versus CMS 
unclassified samples (reclassified by the imCMS classification) 
Table S3: Univariate Cox proportional hazards regression on classified 
samples of the FOCUS cohort 
Table S4: Univariate Cox proportional hazards regression on classified 
samples of the TCGA cohort 
Table S5: Univariate Cox proportional hazards regression on 
unclassified samples of the TCGA cohort 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/645143doi: bioRxiv preprint first posted online May. 23, 2019; 
